| Theme | Gastrointestinal Lymphoma -- Recent Advances in the Diagnosis and Management | |
|---|---|---|
| Title | Diagnosis and Treatment of Gastric Diffuse Large B-cell Lymphoma | |
| Publish Date | 2012/12 | |
| Author | Akira Tari | Division of Gastroenterology , Department of Internal Medicine, Hiroshima Red Cross Hospital & Atomic-Bomb Survivors Hospital |
| Author | Hideki Asaoku | Department of Clinical Laboratory, Hiroshima Red Cross Hospital & Atomic-Bomb Survivors Hospital |
| Author | Kouzou Kashiwado | Department of Radiology , Hiroshima Red Cross Hospital & Atomic-Bomb Survivors Hospital |
| [ Summary ] | Half of gastric malignant lymphomas are diffuse large B-cell lymphomas (DLBCLs) which are aggressive lymphomas. They are a group of heterogenic disorders consisting primarily of DLBCL transformed from extranodal marginal zone lymphomas of mucosa-associated lymphoid tissue (MALT lymphoma) and de novo DLBCL. Clinical staging and the depth of tumors evaluated by endoscopic ultrasonography (EUS) are important for making decisions on therapeutic methods. The standard therapy recommended for localized DLBCL is 3 cycles of R-CHOP with involvedfield radiotherapy (IF-RT) or 6 cycles of R-CHOP with or without IF-RT. It has been reported that Helicobacter pylori (H. pylori) eradication frequently leads H. pylori-positive patients with macroscopically superficial lesion without invasion into the deep submucosal layer to complete remission. Treatment for late stage gastric DLBCL is decided on according to the treatment for nodal DLBCL. | |